Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Merck"


25 mentions found


It's Moderna's second-ever commercially available product after its Covid vaccine, which has seen demand plunge as the world emerges from the pandemic and relies less on protective shots and treatments. He added that "we've been having quite intense discussions with governments across Europe" to get Covid vaccine supply from Moderna. He is referring to the European Union's massive renegotiated Covid vaccine supply contract with Pfizer and its German partner BioNTech . Its shares are up nearly 20% this year on increasing confidence around its pipeline and messenger RNA platform, which is the technology used in its Covid vaccine and RSV shot. Moderna is also developing a stand-alone flu shot, a personalized cancer vaccine with Merck and shots for latent viruses, among other products.
Persons: It's Moderna's, Stephane Bancel, we've, Bancel, BioNTech, Moderna, I'm Organizations: Moderna Inc, Moderna, Pfizer, GSK, LSEG, Wall, Research, Merck Locations: Cambridge , Massachusetts, Europe, U.S, Moderna, Ukraine
Revenue of $695 million was also higher than the $686 million expected. Adjusted earnings of 5 cents per share topped the loss of 2 cents per share forecasted by analysts polled by FactSet. Additionally, Howmet increased its quarterly dividend to 8 cents per share from 5 cents per share, to be payable Aug. 26. JetBlue — Shares jumped 4% after the airline said adjusted earnings per share was 8 cents for the second quarter. Analysts expected a profit of $2.80 per share on revenue of $1.18 billion, according to StreetAccount.
Persons: Woodward, FactSet, LSEG, Archer, Gamble —, Leidos, StreetAccount, — CNBC's Michelle Fox, Hakyung Kim, Lisa Kailai Han, Alex Harring, Jesse Pound, Fred Imbert, John Melloy Organizations: CNBC, Delta Airlines, Microsoft, FactSet, Inc, , Technology, Merck —, pharma, Semiconductor, Bank of America, Pfizer —, Pfizer, Varonis Systems, Howmet Aerospace, Corning, LSEG, Daniels, Midland, JetBlue —, Revenue, PayPal —, PayPal, Procter, Gamble, U.S . Pentagon Locations: FactSet .
Merck : The drugmaker reported a better-than-expected quarter. It raised its full-year sales outlook but was still a little short of estimates. Jim Cramer said Tuesday he would take advantage of the dip and buy Merck ahead of the benefit from this drug. Pfizer : Better-than-expected sales and adjusted earnings, as well as a full-year outlook raise, were not enough to keep the stock higher. PayPal : The digital payments company reported a better-than-expected quarter.
Persons: Jim Cramer's, Jim Cramer, Cramer, Alex Chriss, Anthony Noto Organizations: CNBC, Club, Merck, FDA, Pfizer, PayPal, Aerospace
Chart of the Day: Merck
  + stars: | 2024-07-30 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChart of the Day: MerckMerck is down 10% today. The Investment Committee discuss the biotech sector.
Persons: Merck Merck Organizations: Merck
Check out the companies making headlines in midday trading: JetBlue — The airline soared almost 20% after reporting second-quarter earnings that beat analysts' expectations . The Phoenix-based grocery chain also raised its full-year earnings guidance, forecasting revenue rising between 9% and 10%, compared to analysts' 8.2% consensus growth estimate. Revenue of $695 million was higher than the $686 million analysts has estimated. Lattice Semiconductor — Shares pulled back 8.5% after second-quarter earnings and current-quarter revenue guidance came in below expectations. Howmet Aerospace — The aerospace manufacturer rallied 14% after second-quarter earnings and revenue beat Wall Street estimates.
Persons: Varonis, Woodward, FactSet, LSEG, Howmet, Corning, Gamble —, Stanley Black, Decker, , Alex Harring, Samantha Subin, Lisa Kailai Han, Hakyung Kim Organizations: JetBlue —, New, Revenue, Systems, FactSet, Inc, , Technology, Semiconductor, Bank of America, CNBC, Delta Air Lines, Microsoft, Merck, Howmet Aerospace, Wall, PayPal, LSEG, Procter, Technologies Locations: New York City, LSEG, New Jersey, Cincinnati, Connecticut
Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion on increased demand for key products, particularly its oncology treatments. That's only slightly higher than the $63.1 billion to $64.3 billion guidance the company provided in April. Merck reported $16.11 billion in revenue for the quarter, up 7% from the same period a year ago. Some analysts expect that worldwide sales of Winrevair could reach $5 billion by 2030.
Persons: Keytruda, Merck Organizations: Merck, Harpoon Therapeutics, LSEG, Prometheus Biosciences Locations: Rahway , New Jersey, U.S
3-Stock Lunch: Merck, PayPal and JetBlue
  + stars: | 2024-07-30 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3-Stock Lunch: Merck, PayPal and JetBlueVictoria Greene, G Squared Private Wealth, joins 'Power Lunch' to discuss stock plays for three stocks.
Persons: JetBlue Victoria Greene Organizations: Merck, PayPal, JetBlue, Wealth
Tuesday's rapid fire: Merck, Pfizer, PayPal, Howmet, SoFi
  + stars: | 2024-07-30 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTuesday's rapid fire: Merck, Pfizer, PayPal, Howmet, SoFiJim Cramer looks at five stock outside the CNBC Investing Club portfolio.
Persons: SoFi Jim Cramer Organizations: Merck, Pfizer, PayPal, CNBC, Club
Stock futures were flat in overnight trading Monday as investors awaited key corporate earnings and the beginning of the Federal Reserve's policy meeting. S&P 500 futures and Nasdaq 100 futures both traded 0.1% higher. That compares to a five-year average earnings beat rate of 77%. "Both 2024 and 2025 consensus EPS are holding up, with 2024 EPS tracking a typical non-recessionary year revision trend. "Inflation is trending lower, supporting Federal Reserve rate cuts," said Seema Shah, chief global strategist at Principal Asset Management.
Persons: Savita Subramanian, Jerome Powell, Seema Shah Organizations: New York Stock Exchange, Stock, Dow Jones, Nasdaq, Merck, Pfizer, PayPal, Procter, Gamble, JetBlue, Microsoft, Devices, Bank of, Fed, Asset Management
Here are JPMorgan's top drug stock picks into earnings
  + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com   time to read: +3 min
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.
Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, , Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo
As for Club earnings, we got positive results from life sciences company Danaher and industrial firm Dover. Ford was a major disappointment and its nearly 20% stock drop for the week was the worst performer in the portfolio. In the week ahead, it's going to be another big week of earnings with the four mega-cap names and 10 other Club names set to report. Linde : We're looking for more of the same — steady earnings growth; 6% is the Street estimate. End market commentary will also help us better formulate our view of the economy — and in turn the stock market.
Persons: Russell, Jerome Powell's, Ford, Stanley Black, Decker, We're, we'll, Elliott, we've, We'll, Kraft Heinz, Vita Coco, COCO, Lam, SIRI, WEN, Jim Cramer's, Jim Cramer, Jim, Michael M Organizations: Nasdaq, Dow, Communication, Honeywell, YouTube, Procter & Gamble, Devices, Microsoft, Starbucks, GE Healthcare, DuPont, Meta, Apple, Coterra Energy, Linde, Silo AI, Elliott Management, GE HealthCare, Amazon, Apple Intelligence, U.S, Labor, Fed, Networks, Procter, Gamble, PayPal, Pfizer, BP, JetBlue Airways, Merck, Solar Inc, Caesars Entertainment, Electronic Arts, EA, Nation Entertainment, Boeing, Cruise, Mastercard, Teva Pharmaceutical, Hess Corp, Arm Holdings, Qualcomm, Lam Research, Western, eBay, EBAY, MGM Resorts, MGM, ConocoPhillips, Mobileye, Canada Goose Holdings, Hershey, Toyota, Dominion Energy, Air Products & Chemicals, Southern Company, International, Coterra Energy Intel, Coinbase, Booking Holdings, LIN, Exxon Mobil, Chevron, LyondellBasell Industries, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, Santiago, Getty Locations: Dover, Eaton, Amazon, China, destocking, Corning, New York City
On Friday, the tech-heavy S & P 500 and Nasdaq Composite ended the week with losses, down 0.8% and 2.1%, respectively. However, the bulk of Magnificent Seven results is set for release in the week ahead. As it is, all seven of the Magnificent Seven companies closed out the week with losses. FOMC meeting, July jobs report Elsewhere, investors will also be reviewing the latest Federal Reserve interest rate decision set for release on Wednesday. Traders will also get insight into the labor market next week, with the release of the July jobs report on Friday.
Persons: Russell, Ryan Grabinski, John Belton, Tesla, Belton, FactSet, Stanley Black, Decker, Lam, Kraft Heinz, Ingersoll Rand Organizations: Nasdaq, Dow Jones Industrial, Microsoft, Facebook, Apple, Nvidia, 2H, 3Q, Gabelli, Traders, Dallas Fed, Semiconductor, Nation Entertainment, Electronic Arts, Starbucks, Match Group, Caesars Entertainment, Corning, Howmet Aerospace, Procter, Gamble, Pfizer, Merck, Co, PayPal, ADP, Civilian Workers, Chicago PMI, MGM Resorts International, Allstate, Lam Research, eBay, Qualcomm, Western, Cruise Line Holdings, Hess, Boeing, Mobile, Marriott International, GE Healthcare Technologies, Generac Holdings, Mastercard, Labor, PMI, Manufacturing, Intel, Holdings, Motorola Solutions, Technology, Air Products, Chemicals, Jobs, Exxon Mobil, Chevron Locations: Chicago, Albemarle, Kellanova, Hershey, Moderna
A third of the S & P 500 companies are set to report earnings next week. As the busiest week of earnings season approaches, here are some companies that have historically posted a beat and rallied afterward. Amazon , Apple , Merck and Exxon Mobil are among the companies slated to release their quarterly results. With this in mind, Bespoke Investment Group screened for companies reporting next week whose quarterly earnings have managed to beat consensus analyst estimates at least 75% of the time. Additionally, the stocks in the screener all have gained on average 1.5% the day of or following their earnings release.
Persons: Oppenheimer, Meta's, Steve Madden Organizations: Apple, Merck, Exxon Mobil, Investment, Meta, Nasdaq, Mastercard, Bank of America Locations: China, Wednesday's
Morgan Stanley says it's time for stock-picking in Europe as earnings season and rate cuts are imminent. Stock-level dispersion refers to the range of returns for stocks, while market breadth tracks the number of stocks going up relative to those declining. It named its top picks for Europe, which are its analysts' "highest conviction ideas" within the universe of stocks that they cover. Morgan Stanley called Commerzbank "one of the best yield payers in the sector," and is strongly profitable. "Repsol's financial framework also remains solid, where there is both ability and willingness for high distributions and dividend growth," Morgan Stanley analysts wrote.
Persons: Morgan Stanley, — CNBC's Michael Bloom Organizations: Europe, Merck, Electronics Locations: Europe
3 buys and a bail: Merck, Abbott, Cigna, and Zoom
  + stars: | 2024-07-09 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3 buys and a bail: Merck, Abbott, Cigna, and ZoomGina Sanchez, chief market strategist at Lido Advisors, joins CNBC's 'The Exchange' to discuss four stocks: Merck, Abbott, Cigna, and Zoom.
Persons: Abbott, Cigna, Zoom Gina Sanchez Organizations: Merck, Lido Advisors
Six years ago, an outspoken music executive named Merck Mercuriadis kicked off a new wave of dealmaking in the industry when his company, Hipgnosis, began buying up the song catalogs of artists like Neil Young, Shakira, Justin Bieber and the Red Hot Chili Peppers. In the company’s complex structure, Hipgnosis Songs Fund is an “investment trust,” which is listed on the London Stock Exchange and owns the rights to tens of thousands of songs. A separate company, Hipgnosis Song Management — which has been run by Mercuriadis — is its “investment adviser,” doing much of the dealmaking and administration work for those songs. In 2021, Blackstone invested $1 billion to take majority control over the adviser firm. The board of Hipgnosis Songs Fund voted on Monday to accept Blackstone’s offer of $1.6 billion for the company’s assets, the company announced early Tuesday.
Persons: Merck Mercuriadis, Neil Young, Shakira, Justin Bieber, Beyoncé, Elton John, Mercuriadis —, , Blackstone Organizations: London Stock Exchange
The iShares U.S. Pharmaceuticals ETF (IHE) is up 9% since July 2015, when it hit a fresh all-time high. All of the back-and-forth movement since 2015 has produced what could be a monstrous bullish pattern. But we're trying to capture a major breakout from an area that's done next to nothing in nearly a decade. INVA, on the other hand, bottomed in March 2023, and just recently broke out of a large inverse head & shoulders pattern. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.
Persons: IHE, Eli Lilly, Johnson, JNJ, MRK, Frank Cappelleri Organizations: U.S . Pharmaceuticals, IHE, Merck, CNBC, NBC UNIVERSAL Locations: U.S, LLY
JPMorgan boosted its price target on shares of Apple to $245 each from $225 after the firm raised iPhone volume expectations in 2025 and 2026 due to artificial intelligence upgrades. More price-target hikes for Nvidia : Wells Fargo went to $155 a share from $125 at Wells Fargo while Rosenblatt Securities went to $200 from $140. Piper Sandler called the sell-off in Celsius Holdings overdone and reiterated its $90 price target and buy-equivalent rating. Meanwhile, Stifel increased its price target on the memory chipmaker's stock to $165 a share from $145 ahead of earnings June 26. Netflix 's price target raised to $750 a share from $700 by analysts at Loop Capital.
Persons: Wells Fargo, Piper Sandler, Kroger, Lennar, Netflix's, Jim Cramer's, Jim Cramer, Jim, Nvidia Piper Sandler, Merck Micron Lennar Piper Sandler Organizations: JPMorgan, Apple, Nvidia, Rosenblatt Securities, Holdings, BMO Capital, Kroger, Albertsons, Merck, Food and Drug Administration, Investors, Micron, Bank of, Netflix, Loop, NFL, Jim Cramer's Charitable, CNBC, Holdings BMO Capital, Merck Micron Locations: Wells, Bank of America's, Miami, U.S
The Food and Drug Administration on Monday approved Merck 's new vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia, the drugmaker said. It's the first pneumococcal conjugate vaccine designed specifically for adults and aims to provide broader protection than the available shots on the market, according to the drugmaker. Healthy adults can suffer from pneumococcal disease. Around 150,000 U.S. adults are hospitalized with pneumococcal pneumonia each year, Platt said. Death from the more serious form of the disease is highest among adults 50 and above, Merck said in a release in December.
Persons: Merck, Merck's, Heather Platt, Platt Organizations: Drug Administration, CNBC, Centers for Disease Control
F.D.A. Panel Weighs MDMA Therapy and Its Risks
  + stars: | 2024-06-04 | by ( Andrew Jacobs | ) www.nytimes.com   time to read: +1 min
The Food and Drug Administration is weighing whether to approve the use of MDMA, also known as Ecstasy, for treatment of post-traumatic stress disorder. An independent advisory panel of experts will review studies on Tuesday and is expected to vote on whether the treatment would be effective and whether its benefits outweigh the risks. The panel will hear from Lykos Therapeutics, which has submitted evidence from clinical trials in an effort to obtain agency approval to sell the drug legally to treat people with a combination of MDMA and talk therapy. Methylenedioxymethamphetamine (MDMA) is a synthetic psychoactive drug first developed by Merck in 1912. After being resynthesized in the mid-1970s by Alexander Shulgin, a psychedelic chemist in the Bay Area, MDMA gained popularity among therapists.
Persons: Alexander Shulgin Organizations: Drug Administration, Lykos Therapeutics, Merck Locations: Bay
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.
Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna
Dick's Sporting Goods — The sporting goods retailer popped 7.7% after reporting an earnings and revenue beat for its fiscal first quarter. It now expects earnings per share to be between $13.35 and $13.75, up from its prior range of $12.85 to $13.25. Robinhood — The stock broker shares jump 1.6% in premarket after the trading startup announced its first-ever share buyback plan. Chewy posted earnings per share of 15 cents, topping a FactSet estimate of just 4 cents per share. Cava — The stock fell 5% in premarket even though the restaurant chain posted earnings and revenue for the first quarter that topped expectations.
Persons: Dick's, Robinhood, Chewy, Cava, LSEG, CNBC's David Faber, Merck, , Jesse Pound, Michelle Fox, Lisa Han, Sarah Min, Brian Evans, Hakyung Kim Organizations: ConocoPhillips —, Marathon Oil, Goods, LSEG . American Airlines —, United Airlines —, Jefferies, United Airlines, Google, HubSpot, Merck Locations: American, premarket
Apple and Nvidia, our two "own, don't trade" stocks were also the top performers among the entire 33 stock Club portfolio. When the Federal Reserve at some point removes its asset cap on Wells Fargo, Scharf said corporate lending and trading will be areas of growth for the bank. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Hess, Merck, Morgan Chittum, Charlie Scharf, Scharf, Wells, Wells Fargo's, " Scharf, it's, Wells Fargo, Eli Lilly, CNBC's David Faber, Locker, Jim Cramer's, Jim Organizations: CNBC, Dow, Nvidia, American Airlines, Tech, Apple, Microsoft, ConocoPhillips, Chevron, Banking, Investing Club, Wells, Bernstein's, Investment Banking, Wealth Management, Federal Reserve, FDA, Club, Costco, Broadcom, Jim Cramer's Charitable Locations: Wells Fargo
Stock futures were little changed Tuesday night after the Nasdaq Composite rose to a fresh record. S&P 500 futures ticked down 0.06%, while Nasdaq 100 futures hovered near the flatline. The tech-heavy index was an outlier, however, as the S&P 500 edged higher by just 0.02%, and the 30-stock Dow slid nearly 0.6%, dragged lower by a decline in Merck shares. The S&P 500 is up 5.4% this month, while the Dow has advanced 2.7%. Indeed, fed funds futures trading data suggests a nearly 54% chance that rates will hold steady in September, according to the CME FedWatch Tool.
Persons: Dow, Tom Lee Organizations: Nasdaq, Dow Jones, . American Airlines, JetBlue, Southwest Airlines, Nvidia, Merck, Dow, Federal, Fundstrat Global Advisors
A new generative AI tool can create those studies in minutes. That directive informed Atropos' development of ChatRWD, which Atropos Health launched in beta form in October to 75 customers. Atropos says it's the first generative AI tool to create publication-grade studies from clinical data in minutes. AdvertisementAtropos' $33 million Series B funding follows Atropos' $14 million Series A in August 2022, bringing the company's total funding to $54 million. See the 22-slide pitch deck Atropos Health used to raise $33 million in Series B funding.
Persons: , Brigham Hyde, Valtruis, Jim Breyer's Breyer, Laurene Powell Jobs, Nigam Shah, Saurabh, Hyde, Atropos, Green Button, Green, Johnson, Johnson's Janssen Organizations: Service, Business, Atropos, Cencora Ventures, McKesson Ventures, Merck GHI Fund, Presidio Ventures, Stanford University, National Institutes of Health, Atropos Health, pharma Locations: Geneva, Arcadia
Total: 25